Sp190
A GENERAL OVERVIEW OF QUALITY ASSURANCE PROGRAMS AND ADVERSE EVENT REPORTING
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
As a procedural specialty, adverse events and complications will touch every provider in the course of their career. This session will provide attendees an overview of this aspect of our professional responsibility and response to adverse events. The session will start with an overview of how to create a culture of reporting and quality assurance. Following this overview, thought leaders in the area will discuss practical tips on how to respond to patients and colleagues after an adverse event. The session will close with an innovative approach to teaching and practicing these skills. Clinicians, program directors and practice and QI leaders will benefit from attending this session and leave with new insights and practical approaches on this topic.
As a procedural specialty, adverse events and complications will touch every provider in the course of their career. This session will provide attendees an overview of this aspect of our professional responsibility and response to adverse events. The session will start with an overview of how to create a culture of reporting and quality assurance. Following this overview, thought leaders in the area will discuss practical tips on how to respond to patients and colleagues after an adverse event. The session will close with an innovative approach to teaching and practicing these skills. Clinicians, program directors and practice and QI leaders will benefit from attending this session and leave with new insights and practical approaches on this topic.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
